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ABSTRACT
Depression is the second leading cause of disability worldwide, and is associated with
substantial functional impairment and poor health implications in older adults. These adverse
outcomes are exacerbated in older adults who exhibit comorbid depression and cerebrovascular
burden (CVB). Given that the population of older adults is projected to double by year 2050, a
process model of the development of depression in later-life and a subsequent clear delineation
of the relationship between CVB and depression is paramount. One explanation of this process
of disease development is the vascular depression theory, however alternative hypotheses have
not been exhaustively falsified and the literature consists of methodological barriers that produce
potentially unreliable results. The goals of this thesis are (1) to examine the interrelationship
between CVB and depressive symptomatology from mid-life to later-life, and (2) to assess a
potential genetic modifier of the CVB/depressive symptomatology relationship. Participants
were drawn from the Wisconsin Longitudinal Study, which represents the 1957 graduating class
from Wisconsin high schools. Data was drawn from three waves (1993, 2004, and 2011),
spanning 18 years. Study 1 utilized a dual-change model to evaluate the relationship between
CVB and depressive symptomatology from mid-life to later-life. Results indicated that
depressive symptomatology at both follow-up waves was predicted by earlier depressive
symptomatology. Prior CVB significantly predicted future depressive symptomatology in both
2004 and 2011. Depressive symptomatology in 2004 significantly predicted CVB in 2011. Thus,
CVB significantly predicted future depressive symptomatology even after accounting for prior
depressive symptomatology. Study 2 utilized a repeated-measures ANOVA and a moderated
path structural model to evaluate the moderating effect of ApoE carriage on the relationship
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between CVB and depressive symptomatology. Results indicated that ApoE carriage has no
significant main effect on depressive symptomatology, nor is it a significant moderator of the
relationship between CVB and depressive symptomatology. Overall findings strongly support
the vascular depression theory, and do not implicate ApoE carriage in the manifestation of
depressive symptomatology. Future research should longitudinally evaluate the relationship
between CVB and depressive symptomatology across a greater number of defined time points
and with a more diverse sample. Lastly, future research should continue to identify genetic risk
factors that influence the development of detrimental disease processes.
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CHAPTER 1: INTRODUCTION
Depression is the second leading cause of disability worldwide, and is associated with
significant functional impairment and poor health implications in older adults (Bruce, Seeman,
Merrill, & Blazer, 1994; Ferrari et al., 2013; Lichtenberg, Gibbons, Nanna, & Blumenthal,
1993). When combined with comorbid cerebrovascular burden (CVB), the detrimental effects of
depression in later-life are exacerbated (Yochim, Mast, & Lichtenberg, 2003). The number of
adults over the age of 65 in the United States is projected to double by year 2050, comprising
20% of the total U.S. population. This imminent increase in the proportion of older adults
prioritizes the pursuit to effectively predict, prevent, and treat detrimental disease processes (i.e.,
comorbid CVB and depression).
Past efforts to conceptualize the development of depressive symptomatology in later-life
have generated the vascular depression theory, whereby vascular disease may “predispose,
precipitate, or perpetuate” depressive symptoms among older adults (Alexopoulos et al., 1997, p.
915). Vascular depression theory posits a temporal sequence of disease development such that
depressive symptomatology develops as a consequence of CVB, however two contrary
hypotheses are evident in the literature. First, depression is episodic in nature, with past
depression being among the strongest predictors of future depression (Djernes, 2006; Lewinsohn,
Zeiss, & Duncan, 1989). Second, a review of the health psychology literature broadly concludes
depression as the antecedent to a subsequent increase in vascular load, suggesting a directly
opposite system of comorbid CVB and depressive symptomatology development to that
proposed in the vascular depression theory. Without adequate examination of these alternative
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hypotheses, CVB cannot be conclusively identified as the catalyst of increased depressive
symptomatology in later-life.
A second avenue through which researchers are attempting to delineate the development
of depressive symptomatology in later-life is through the identification of neurobiological
correlates. One meta-analysis identified apolipoprotein E (ApoE) as one of the most strongly
associated genes with major depressive disorder (MDD; Lopez-Leon et al., 2008). ApoE is most
prominently recognized as a determinant in the development of Alzheimer’s disease (AD),
however it has also been implicated in the manifestation of Parkinson’s disease and Wilson’s
disease (Li et al., 2004; Liu, Kanekiyo, Xu, & Bu, 2013; Schiefermeier et al., 2000). Specifically,
the presence of the ApoE-4 allele has been related to detrimental health outcomes, such as
greater risk of developing, and lower age of onset for, certain neurodegenerative diseases
(Blacker et al., 1997; Farrer et al., 1997; Li et al., 2004; Schiefermeier et al., 2000). Given the
neurobiological correlates of disordered mood and CVB, it is logical to assume a similar effect of
ApoE carriage on the development of depressive symptomatology, whether it is a direct effect on
the development of depressive symptoms or a moderating effect on the relationship between
CVB and depressive symptomatology. However, a review of the literature reflects inconsistent
findings, such that some studies show a detrimental effect of ApoE-4 on depressive
symptomatology (Butters et al., 2003; Rigaud et al., 2001; Skoog et al., 2015), while other
studies show no association between the two constructs (Cervilla, Prince, Joels, Russ, &
Lovestone, 2004; Surtees et al., 2009).
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Goals of this thesis are to examine the relationship between CVB and depressive
symptomatology from mid-life to later-life (Study 1), and to examine whether ApoE carriage
moderates the effect that CVB has on the development of depressive symptomatology (Study 2).
The present thesis addresses common methodological barriers (i.e., small sample sizes and
samples that are too young for an apparent relationship, listwise deletion of participants with
missing data, and cross-sectional designs) to most effectively evaluate the relationships between
CVB, depressive symptomatology, and ApoE. Results of this thesis may improve our
understanding of interrelated disease processes, thus informing integrated healthcare delivery.
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CHAPTER 2: THE IMPACT OF CEREBROVASCULAR BURDEN ON
DEPRESSIVE SYMPTOMATOLOGY FROM ADULTHOOD TO LATERLIFE
Introduction
The number of adults over the age of 65 in the United States is projected to reach an
estimated 88.5 million by year 2050, and will constitute 20% of the total United States
population (Shrestha & Heisler, 2011). Depression is a common and multi-faceted late-life
comorbidity in this growing population, and one that imposes significant functional impairment
and physical health implications among older adults (Bruce et al., 1994; Lichtenberg et al., 1993;
Yochim et al., 2003). Past efforts to conceptualize the phenomenon of late-life depression,
particularly late-onset depression, have yielded the vascular depression theory. Alternate
perspectives from the epidemiological and health psychology literatures call into question some
core assumptions of the vascular depression theory. To our knowledge, those competing
perspectives have not been directly contrasted using longitudinal data.
The empirical perspective reflects a consistent finding that depression has a chronic and
recurrent trajectory, with past depression being among the strongest predictors of future
depression (Djernes, 2006). For instance, past work has found that the probability of the
recurrence of depressive episodes is positively associated with the number of previous episodes
(Lewinsohn et al., 1989). Vascular depression theory, however, posits a temporal sequence such
that depressive symptomatology emerges in later-life only after the development of significant
cerebrovascular burden (CVB; Alexopoulos et al., 1997). The trajectory posited by vascular
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depression theory neglects the influence of prior episodes of depression, and thus may confound
the effects of earlier CVB with prior depressive symptomatology.
The second alternative perspective to the vascular depression hypothesis is based on the
health psychology literature, and posits that depression has not only been identified as a
consequence of disordered health; a review of the health psychology literature broadly concludes
that depression is an antecedent to subsequent increases in vascular load, suggesting a hypothesis
that is directly contrary to vascular depression theory. For instance, depressed mood is positively
associated with medical noncompliance (Carney, Freedland, Eisen, Rich, & Jaffe, 1995; Glazer,
Emery, Frid, & Banyasz, 2002; Wang et al., 2002). In turn, substandard medical regimen
compliance engenders poor health outcomes, particularly for people with chronic comorbidities
that affect the brain such as hypertension, various heart problems, and diabetes. Depressed
individuals are more likely to smoke and to have ever smoked compared to their non-depressed
counterparts (Covey, Glassman, & Stetner, 1998; Glassman et al., 1990). Longitudinally,
depression has been consistently indicated as a predictor of CVB, as demonstrated with the
development of hypertension at 5-year follow-up (Davidson, Jonas, Dixon, & Markovitz, 2000),
the diagnosis of coronary heart disease during a 7-year study (Nabi et al., 2010), and incident
acute myocardial infarction and mortality in a 27-year follow-up (Barefoot & Schroll, 1996).
Depression has also been shown to increase an individual’s vulnerability to the onset of type 2
diabetes (Knol et al., 2006) as well as incident hypertension (Jonas, Franks, & Ingram, 1997).
Therefore, it may be premature to assume that CVB is the antecedent in the hypothesized CVBdepression relationship.
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Extant research has not examined how high CVB in mid-life predicts depressive
symptomatology in later life over and above mid-life depressive symptomatology. Nor has past
vascular depression research examined the competing and seemingly contradictory hypothesis
(i.e., depression as the antecedent to CVB). The present study is an attempt to elucidate this
apparent conflict by utilizing longitudinal data and a three-faceted hypothesis. Specifically, the
longitudinal inter-relationships between CVB and depression will be examined across three
waves spanning mid-life (age 53.20 years) to later-life (age 71.21 years). The temporal sequence
between depressive symptomatology and the manifestation of CVB among aging adults will be
examined using a dual change model. This model tests the hypotheses that (1) mid-life
depressive symptomatology will predict later-life depressive symptomatology, and that (2) CVB
in mid-life will positively predict future depressive symptomology even after controlling for past
depressive symptomatology, as posited by the vascular depression theory (Alexopoulos et al.,
1997). The inverse hypothesis suggested by Barefoot and Schroll (1996), Nabi et al. (2010), and
Davidson et al. (2000), that (3) mid-life depressive symptomatology will predict later-life CVB,
is also examined by this model. This dual change model will include both A) autoregressive
pathways reflecting the hypothesized relationship between past CVB on future CVB and past
depressive symptomatology on future depressive symptomatology, respectively; and B) crosslagged pathways reflecting the hypothesized effect of past CVB on future depressive
symptomatology and of past depressive symptomatology on future CVB, respectively (see
examined model in Figure 2.1). Based on past work, sex, education, and income were selected a
priori as control variables.
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Method
Participants
The present study will utilize data collected through the Wisconsin Longitudinal Study
(WLS). The WLS is a longitudinal cohort study that includes over 10,000 randomly selected
representatives of the 1957 high school graduating class from Wisconsin. Participants were
originally recruited in 1957 with an in-person questionnaire, then follow up data collections were
gathered in 1964 (mail survey of parents), 1975 (telephone survey), 1993 (telephone and mail
surveys), 2004 (telephone and mail surveys), and 2011 (in-person survey and mail survey; Herd,
Carr, & Roan, 2014). The WLS includes a wide breadth of information on its participants,
including demographics, mental health status, medical health status, genetic variables, and
measures of cognition. The initial goals of the WLS were to assess the demand for post-high
school education, to determine if promising high school students were attending college or
university, and what circumstances contributed to these education plans via a state-sponsored
questionnaire (Little, 1958). Follow up studies were originally conducted to examine the extent
to which family background and childhood experiences and aspirations affected educational and
occupational attainment (Herd et al., 2014). Since 1991, the WLS has been principally funded by
the National Institutes for Health and National Institute on Aging, with additional support
provided by the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation,
and the Graduate School of the University of Wisconsin-Madison (Herd et al., 2014).
The data relevant to this study is found in the 1993, 2004, and 2011 data collection
waves. Participants who have missing data within the variables of interest were excluded from
the study.
7

Measures
Demographic Variables. Age, sex, and income were self-reported by the participant.
Education was assessed as self-reported years of formal schooling.
Cerebrovascular Health Variables. All medical variables used in this study were
collected by self-report. Participants were asked “Has a doctor ever told you that you have . . .”
high blood pressure or hypertension; high blood sugar; diabetes; heart attack, coronary heart
disease, angina, congestive heart failure, or other heart problems; stroke. In this study, these
comorbidities were grouped into three categories by organ system. Presence of hypertension was
identified by endorsement of high blood pressure or hypertension. Presence of blood sugar
dysregulation was identified by endorsement of high blood sugar or diabetes. Presence of cardiac
disease was identified by endorsement of heart attack, coronary heart disease, angina, congestive
heart failure, or other heart problems. Participants endorsing a history of stroke were excluded,
as these individuals have been shown to be more likely to experience subsequent mood
dysregulation (Bour et al., 2009).
Total CVB. Total CVB is a continuous measure of cerebrovascular risk factors,
comprising a participant’s scores on the hypertension, high blood sugar/diabetes, and heart
disease measures and emitting a total score ranging from 0-3.
Outcome Variable
Depression. Depression was measured using the Center for Epidemiological Studies
Depression (CES-D) measure (L.S. Radloff, 1977). The CES-D collapses ranges of scores (0, 12, 3-4, and 5-7, then recodes these ranges to 0, 1, 2, or 3), for an individual’s total score ranging
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from 0-60. The internal consistency of the CES-D is high for older adults (coefficient alpha .85
to .90), as is the validity of the measure (Lenore S. Radloff & Teri, 1986). Although the CES-D
has a suggested cutoff score for probable depression, the present study will utilize this measure
as a continuous degree of depressive symptomatology.
Statistical Methods
A dual-change model was employed to represent the relationship between CVB and
depressive symptomatology across three time points ranging from mid-life (year 1993, mean age
53.20 years) to later-life (year 2011, mean age 71.21 years; see Figure 2.1). This model includes
autoregressive pathways modeling to demonstrate, for example, the effect of CVB at time 1 on
CVB at time 2. This model also includes cross-lagged pathways representing the hypothesized
causal effect of CVB on depressive symptomatology, and vice-versa, over time. Full information
maximum likelihood estimation (FIML) was utilized to prevent listwise deletion and, in turn, to
prevent the underrepresentation of at-risk respondents on variables associated with mortalitybased attrition (e.g., those who are socially marginalized which may affect one’s access to
healthcare, or those carrying greater medical burden). Data was prepared in SPSS and the
structural equation model analysis was performed utilizing Mplus software program (Muthen &
Muthen, 2012).
Results
The final sample consisted of 5,175 participants. Participant characteristics are provided
in Table 1.1. Mean age of participants was 53 years in 1993, 64 years in 2004, and 71 years in
2011. The largest proportion of the sample that was estimated using FIML was for depressive
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symptomatology; 19.1%, 17.3%, and 23.5% of participants’ depressive symptomatology data
was estimated in 1993, 2004, and 2011, respectively. Participant CVB data was estimated less
frequently, with 12.8%, 0.004%, and 0.006% of participant’s CVB data estimated in 1993, 2004,
and 2011, respectively.
The temporal sequence between depressive symptomatology and the manifestation of
CVB among aging adults was examined using a dual-change model, incorporating three waves
of data (1993, 2004, and 2011; Figure 2.1). Overall, results suggest that the hypothesized model
fit the data very well (RMSEA=0.047; Comparative Fit Index (CFI)=0.963, χ2(57,
N=5175)=8573.411,

p<.00005). With respect to the model’s autoregressive pathways evaluating the

relationship demonstrating how previous CVB effects future CVB, greater CVB in 1993
significantly predicted CVB in 2004 (β=0.492, SE=0.011, p<.001). Further, greater CVB in 2004
was significantly associated with greater CVB in 2011 (β=0.699, SE=0.007, p<.001). The
autoregressive pathways demonstrating the relationship between prior and future depressive
symptomatology revealed a similar relationship, whereby higher CES-D scores in 1993 were
significantly associated with higher CES-D scores in 2004 (β=0.546, SE=0.011, p<.001), and
higher CES-D scores in 2004 were significantly related to higher CES-D scores in 2011
(β=0.603, SE=0.011, p<.001). With respect to the cross-lagged pathways identifying the
relationship between CVB and depressive symptomatology from previous waves to future
waves, greater CVB in 1993 was significantly associated with higher CES-D scores in 2004
(β=0.038, SE=0.013, p=.004). Greater CVB in 2004 was also associated with higher CES-D
scores in 2011 (β=0.027, SE=0.013, p=.042). Conversely, an effect of past CES-D scores on
level of CVB at future waves was only evident in the last wave; higher CES-D scores in 2004
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were significantly positively predictive of level of CVB in 2011 (β=0.022, SE=0.011, p=.038).
Overall, the model accounted for 38.2% of the variance in depressive symptomatology in 2011.
To assess the pathway by which CVB in 1993 significantly predicts depressive
symptomatology in 2011, two indirect pathways were analyzed in the model: (1) CVB in 1993 to
depressive symptomatology in 2011 by way of CVB in 2004, and (2) CVB in 1993 to depressive
symptomatology in 2011 by way of depressive symptomatology in 2004. Both indirect pathways
were statistically significant, whereby CVB in 1993 significantly predicted depressive
symptomatology in 2011 through CVB in 2004 (β=0.013, SE=0.007, p=.042) and CVB in 1993
significantly predicted depressive symptomatology in 2011 through depressive symptomatology
in 2004 (β=0.023, SE=0.008, p=.004).
In addition to the primary variables of interest, all control variables used in the model had
statistically significant pathways dependent upon the wave. Specifically, level of education was
significantly inversely related to the level of CVB in 1993 (β=-0.064, SE=0.015, p<.001), 2004
(β=-0.064, SE=0.013, p<.001), and 2011 (β=-0.042, SE=0.010, p<.001). Level of education was
also significantly inversely related to depressive symptomatology in 2004 (β=-0.029, SE=0.013,
p=.031) and 2011 (β=-0.042, SE=0.013, p=.002). Participant income was significantly inversely
associated with level of depressive symptomatology in 1993 (β=-0.120, SE=0.016, p<.001),
2004, (β=-0.036, SE=0.014, p=.010), and 2011 (β=-0.051, SE=0.014, p<.001). Sex of the
participant was significantly associated with level of CVB in 1993 (β=-0.059, SE=0.015,
p<.001), 2004 (β=-0.088, SE=0.013, p<.001), and 2011 (β=-0.068, SE=0.010, p<.001),
suggesting that male sex is associated with higher levels of CVB. Lastly, sex of the participant
was significantly associated with depressive symptomatology in 1993 (β=0.082, SE=0.015,
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p<.001) and in 2004 (β=0.039, SE=0.013, p=.004), whereby female sex was associated with
higher depressive symptomatology.
Discussion
Results support hypothesis 1 based on the epidemiological depression literature that past
depressive symptomatology was a consistent predictor of future depressive symptomatology.
Results also supported hypothesis 2 based on the vascular depression hypothesis that even after
controlling for the effects of past depressive symptomatology, high CVB still predicted greater
endorsement of depressive symptomatology later in life. Findings partially supported hypothesis
3 based on the health psychology literature that mid-life depressive symptomatology would
predict later-life depressive symptomatology.
These findings address an unexamined assumption of the vascular depression theory. Past
depression has been identified as one of the strongest predictors of future depression (Djernes,
2006; Lewinsohn et al., 1989), however the vascular depression theory assumes a temporal
sequence that indicates CVB as the predecessor and catalyst to a subsequent increase in
depressive symptomatology. Results of this study strongly support the vascular depression theory
by indicating mid-life CVB as a significant risk factor for the development of depressive
symptomatology in later-life above and beyond that associated with depressive symptomatology
earlier in life.
The vascular depression theory focuses primarily on the unidirectional relationship
between CVB and depressive symptomatology, a relationship for which the current results
support. The inverse hypothesis, whereby greater depressive symptomatology at mid-life is
significantly predictive of CVB in later-life, was partially supported in this study. Higher levels
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of depressive symptomatology in 2004 were significantly related to increased CVB in 2011; this
relationship was not evident from 1993 to 2004. This finding corroborates other results
suggesting that depressive symptomatology is associated with subsequent development of
cerebrovascular risk factors such as hypertension, diabetes, and heart disease (Barefoot &
Schroll, 1996; Davidson et al., 2000; Knol et al., 2006; Nabi et al., 2010). This finding highlights
the need for regular depression screening to allow for the identification of risk factors of, and the
implementation of preventative measures for, cerebrovascular disease. Primary care clinics,
where mental health screening and behavioral health specialists are becoming increasingly
common, are one key setting where such interventions may be employed.
The twin indirect effects reflect the hypothesized effect through which CVB predisposes
the development of depressive symptomatology; however, the rate at which CVB in mid-life
precipitates the development of that depressive symptomatology is heterogeneous in its
manifestation. The current results implicate this heterogeneity by reflecting multiple measured
relationships leading to development of depressive symptomatology. One pathway indicated that
CVB in mid-life (1993) precipitated the development of depressive symptomatology earlier
(measured in 2004) in the observed 18-year span; this depressive symptomatology perpetuated
throughout the observed epoch. A second pathway evidenced CVB in mid-life that was
maintained or intensified during the observed 18-year span, from which depressive
symptomatology was precipitated and perpetuated at a later time in the epoch (at the 2011 wave)
compared to the first indirect effect. Given that the current model includes auto-regressive and
cross-lagged pathways among three time points and two outcome variables (i.e., CVB and
depressive symptomatology in 1993, 2004, and 2011), the two aforementioned indirect effects
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were the only ones available to be tested. It is likely that these two measured trajectories reflect
the variable manifestation of vascular depression symptom development. Future research should
examine potential modifiers of which the rate of development of depressive symptomatology due
to CVB is a function.
The primary limitation of this study is the use of a racially homogeneous (Caucasian),
well-educated sample. Future research should seek to replicate these findings with a more
racially and socioeconomically diverse sample. A second limitation of this analysis is the use of
self-reported health data in creating the CVB variable. However, this practice is consistent with
past research on clinically defined vascular depression. Further, subjective accounts of medical
burden have yielded high concordance with objective measures (e.g., medical records and
examinations; Bush, Miller, Golden, & Hale, 1989; Psaty et al., 1995). A third limitation exists
in the assessment of chronological change that is imposed by using only three defined time
points over a long span of time (i.e., 18 years). To our knowledge, however, very few datasets
exist that represent such a large number of participants from mid-life to later-life.

Thus,

feasibility of a more thorough analysis of these inter-relationships remains limited.
The findings of this study provide empirical evidence to address an assumption made by
the vascular depression theory that, to our knowledge, has not been adequately evaluated. A
primary question raised by these results is whether treatment of mid- to later-life depression can
prevent the development of chronic cerebrovascular comorbidities such as diabetes,
hypertension, and heart problems among aging adults. With the predicted significant increase in
the proportion of older adults over the upcoming decades, the need to identify risk factors for
disordered health in this aging population is paramount. By implementing preventative
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interventions for depression in at-risk populations (i.e., individuals with high levels of CVB)
earlier in the life span, it may reduce the prevalence of associated detrimental health outcomes
and healthcare utilization.
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CHAPTER 3: THE IMPACT OF APOE ON THE PREDISPOSITION AND
PERPETUATION OF THE VASCULAR DEPRESSION EFFECT
Introduction
Depression in later-life is commonly undetected, despite its recognition as the second
leading cause of disability worldwide, associated substantial functional impairment, and ominous
physical health implications (Bruce et al., 1994; Ferrari et al., 2013; Lichtenberg et al., 1993). In
conjunction with comorbid cerebrovascular burden (CVB), the effects of depression in later-life
are exacerbated (Yochim et al., 2003). Currently the population of adults in the United States
over the age of 65 years surpasses 44 million (U.S. Census Bureau Population Division, 2014).
This number is projected to increase over the upcoming decades, reaching an estimated 88.5
million people by year 2050 and comprising 20% of the total U.S. population (Shrestha &
Heisler, 2011). This surge in the population of older adults has led to a subsequent increase in
scrutiny on the most effective way to predict, prevent, and treat detrimental disease processes.
One avenue by which researchers are examining how best to provide healthcare to older adults is
through the use of genetic sequencing, which has become more affordable in recent years. A
strong emphasis has been placed on relating genetic diatheses with environmental and behavioral
stressors on the development of life-limiting syndromes, allowing for individualized medicine
which is more efficient, economical, and effective in the prevention and treatment of disease
(Cortese, 2007).
In the movement toward identifying neurobiological correlates to physical and behavior
disorders, one meta-analysis identified apolipoprotein E (ApoE) as one of the most strongly
associated genes in terms of the odds ratio for adverse later-life health outcomes, including major
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depressive disorder (MDD; Lopez-Leon et al., 2008). ApoE was first recognized for its
implications in lipoprotein metabolism and cardiovascular disease, and has since become
recognized for its role in cognitive function, immunoregulation, and the manifestation of
Alzheimer’s disease (AD; Mahley & Huang, 1999). ApoE is a polymorphic protein arising from
three alleles: e2, e3, and e4; thus, there are six possible combinations of ApoE carriage that,
when displayed on a continuum, reflect a dimension of ApoE-conferred risk. Allelic frequencies
of ApoE in Caucasian samples are approximately 7% e2, 77% e3, and 16% e4, with
corresponding genotypic frequencies of 0.5% e2/e2, 11% e2/e3, 59% e3/e3, 2% e2/e4, 25%
e3/e4, and 3% e4/e4 (Corder, Lannfelt, Bogdanovic, Fratiglioni, & Mori, 1998). Each allele
combination implies varying substantial functional consequences. A broad review of the
literature indicates e3 as most common in frequency and concomitant to normal functioning,
whereas e2 and e4 are scarcer and have varying functional implications (Mahley & Huang,
1999).
ApoE is more prominently recognized in its relation to the development of AD. Extant
research suggests a dose-dependent effect of ApoE isoforms on amyloid beta peptide clearance,
aggregation, and deposition (Liu et al., 2013). When comparing across isoforms, the presence of
an ApoE-4 allele puts individuals at significantly higher risk for developing AD (for e2/e4, OR =
2.6; for e3/e4, OR = 3.2; for e4/e4, OR = 14.9; Farrer et al., 1997). The presence of ApoE-4 has
also been linked to an earlier onset of AD, such that individuals with the e4/e4 genotype have
been shown to have a mean age of AD onset of 66.4 years compared to all other ApoE
configurations, who show an average AD onset of 71.3 to 73.6 years (Blacker et al., 1997).
Similar effects of ApoE-4 on hastened disease development have been indicated in Parkinson’s
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disease and in Wilson’s disease (Li et al., 2004; Schiefermeier et al., 2000). By contrast, e2 has
been shown to have a protective effect; in one study, individuals with genotypes e2/e2 and e2/e3
showed a 40% risk reduction in the development of AD (Farrer et al., 1997). This protective
effect of ApoE on the development of AD was corroborated by Corder and colleagues (1994),
whereby AD risk was lowest in individuals with the e2/e3 genotype. Further, 23% of AD cases
in this meta-analysis were considered “attributable to the absence of an ApoE-2 allele” (Corder
et al., 1994, p. 180).
Given that ApoE impacts the manifestation of various neurological diseases, it is logical
to presume a similar effect exists by which ApoE carriage would affect the pathophysiology of
depression in later-life. Concurrent with this hypothesis, extant depression literature reflects
substantive parallels with the AD literature. Lopez-Leon and colleagues (2008) found that
individuals who possessed an ApoE-2 allele, compared to the e3 allele, had a risk reduction of
49% in developing MDD; this effect mimics the protective effect seen between ApoE-2 and AD.
Studies have also demonstrated the detrimental effect of ApoE-4, whereby ApoE-4 carriers
exhibited a significantly higher risk of increased depressive symptomatology in older adults,
with odds ratios ranging from 1.75 to 6.1 (Rigaud et al., 2001; Skoog et al., 2015). With regard
to the onset of depression in later-life, the mean age of onset for ApoE-4 carriers was
significantly lower than that for non-carriers (51.4±20.7 years and 58.8±16.8 years, respectively;
Butters et al., 2003). Although results suggesting a link between ApoE and depression are
compelling, the literature also includes studies within which no effect was apparent. For
example, in a study of over 17,500 individuals aged 41 to 80 (mean age 60.9 years), there was no
difference in MDD prevalence across ApoE genotypes (Surtees et al., 2009).
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CVB, Depression, and ApoE: A Potential Intersection
The strongly supported relationship between the CVB and the development of depression
in later life (for review, see Scott & Paulson (Under Review)), in conjunction with the effect that
ApoE genotype has on lipoprotein metabolism and cardiovascular disease, suggests an
intersection of these three constructs. Research examining the relationship between CVB, ApoE,
and depression has been sparse. Some studies have yielded ApoE carriage as a significant
moderator of CVB’s positive predictive effects on depressive symptomatology in older adults
(Lavretsky et al., 2000; Nebes et al., 2001). Not only have ApoE-4 carriers with comorbid CVB
been shown to have greater depressive symptomatology, but they also may experience a greater
number of depressive episodes and have a lower mean age of depression onset (mean age of
onset for ApoE-4 carriers = 50.8 ± 18.7 years; Lavretsky et al., 2000). However, the findings by
Lavretsky et al. (2000) and Nebes et al. (2001) were generated from small sample sizes (16 and
92 participants, respectively), limiting the interpretation of their results.
Longitudinal relationships addressing the relationship between ApoE carriage, CVB, and
later-life depression are relatively few among the literature. Support for the hypothesized model
is dispersed across studies, though no single study has integrated variables into a single, coherent
theoretical or empirical model with an adequately sized sample. An adequate evaluation of
ApoE, CVB, and depressive symptomatology as it relates to aging requires a large sample of
adults over the age of 65 and a longitudinal approach. The present study is the first of our
knowledge to examine how ApoE carriage moderates the relationship between cerebrovascular
health and depression longitudinally from mid-life to later-life.

19

Methods
Participants
The present study will utilize data collected through the Wisconsin Longitudinal Study (WLS).
The WLS is a longitudinal cohort study that includes over 10,000 randomly selected
representatives of the 1957 high school graduating class from Wisconsin. Participants were
originally recruited in 1957 with an in-person questionnaire, then follow up data collections were
gathered in 1964 (mail survey of parents), 1975 (telephone survey), 1993 (telephone and mail
surveys), 2004 (telephone and mail surveys), and 2011 (in-person survey and mail survey; Herd
et al., 2014). The WLS includes a wide breadth of information on its participants, including
demographics, mental health status, medical health status, genetic variables, and measures of
cognition. The initial goals of the WLS were to assess the demand for post-high school
education, to determine if promising high school students were attending college or university,
and what circumstances contributed to these education plans via a state-sponsored questionnaire
(Little, 1958). Follow up studies were originally conducted to examine the extent to which
family background and childhood experiences and aspirations affected educational and
occupational attainment (Herd et al., 2014). Since 1991, the WLS has been principally funded by
the National Institutes for Health and National Institute on Aging, with additional support
provided by the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation,
and the Graduate School of the University of Wisconsin-Madison (Herd et al., 2014).
The data relevant to this study is found in the 1993, 2004, and 2011 waves. Participants
who have missing data within the variables of interest were excluded from the study.
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Measures
Demographic Variables. Age, sex, and income were self-reported by the participant.
Education was assessed as self-reported years of formal schooling.
Cerebrovascular Health Variables. All medical variables used in this study were
collected by self-report. Participants were asked “Has a doctor ever told you that you have . . .”
high blood pressure or hypertension; high blood sugar; diabetes; heart attack, coronary heart
disease, angina, congestive heart failure, or other heart problems; stroke. In this study, these
comorbidities were grouped into three categories by organ system. Presence of hypertension was
identified by endorsement of high blood pressure or hypertension. Presence of blood sugar
dysregulation was identified by endorsement of high blood sugar or diabetes. Presence of cardiac
disease was identified by endorsement of heart attack, coronary heart disease, angina, congestive
heart failure, or other heart problems. Participants endorsing a history of stroke were excluded,
as these individuals have been shown to be more likely to experience subsequent mood
dysregulation (Bour et al., 2009).
Total CVB. Total CVB is a continuous measure of cerebrovascular risk factors,
comprising a participant’s scores on the hypertension, high blood sugar/diabetes, and heart
disease measures and emitting a total score ranging from 0-3.
Genetic Variable
Apolipoprotein E. Saliva samples were collected from participants in 2006-2007 using
Oragene kits and a mail-back protocol (Herd et al., 2014). An additional consent form was
completed for usage of returned saliva samples. DNA genotyping was performed by

21

KBioscience in Hoddesdon, UK, using homogeneous fluorescent resonance energy transfer
technology coupled to competitive allele-specific PCR (Roetker et al., 2012).
Outcome Variable
Depression. Depression was measured using the Center for Epidemiological Studies
Depression measure (CES-D; L.S. Radloff, 1977). The CES-D collapses ranges of scores (0, 1-2,
3-4, and 5-7, then recodes these ranges to 0, 1, 2, or 3), for an individual’s total score ranging
from 0-60. The internal consistency of the CES-D is high for older adults (coefficient alpha .85
to .90), as is the validity of the measure (Lenore S. Radloff & Teri, 1986). Although the CES-D
has a suggested cutoff score for probable depression, the present study will utilize this measure
as a continuous degree of depressive symptomatology.
Statistical Methods
A repeated-measures ANOVA (RM-ANOVA) was employed to evaluate the longitudinal
effect that ApoE has on depressive symptomatology across three waves spanning mid-life (age
53.20 years) to later-life (age 71.21 years). This analysis included an evaluation of the main
effect of ApoE-conferred risk on depressive symptomatology, as well as the interaction between
ApoE-conferred risk and time to assess the change in the expression of ApoE-carriage on
depressive symptomatology as participants age. Further, this analysis included the interaction of
ApoE-conferred risk and CVB to test moderation effects. Baseline sex, education, income, and
marital status were set as control variables. This analysis was run using SPSS Version 22, and
alpha level is .05 unless otherwise stated.
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To model the effect that ApoE-conferred risk has on the relationship between CVB and
depressive symptomatology over time while concurrently addressing methodological barriers in
past work (i.e., listwise deletion), a moderated path model was employed (Figure 2.2). This
model includes autoregressive pathways modeling to demonstrate, for example, the effect of
CVB at time 1 on CVB at time 2. This model also includes cross-lagged pathways representing
the hypothesized causal effect of CVB on depressive symptomatology over time. Interaction
terms representing the effect that ApoE-conferred risk has on the relationship between CVB and
depressive symptomatology in 2004 and in 2011 were included. Full information maximum
likelihood estimation (FIML) was utilized to prevent listwise deletion and, in turn, to prevent the
underrepresentation of at-risk respondents on variables associated with mortality-based attrition
(e.g., those who are social marginalized which may affect one’s access to healthcare, or those
carrying greater medical burden). Based on past work, sex, education, and income were set as
control variables. Data was prepared in SPSS and the structural equation model analysis was
performed utilizing Mplus software program (Muthen & Muthen, 2012).
Results
The final sample consisted of 3,203 participants. Participant characteristics are provided
in Table 1.2. Mean age of participants was 53 years in 1993, 64 years in 2004, and 71 years in
2011. Within the moderated path model, the largest proportion of missing data was depressive
symptomatology; 6.6%, 11.4%, and 17.2% of participants’ depressive symptomatology data was
estimated using FIML in 1993, 2004, and 2011, respectively. Only 0.6% of participants’ CVB
data was missing in 2011. Participants with incomplete data were listwise deleted in the RMANOVA, resulting in a sample size of 2,350 participants.
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Mauchly’s Test of sphericity for the RM-ANOVA was significant (W = .989, χ2(2, N=2350) =
26.730, p < .001), suggesting that the observed matrix does not have approximately equal
variances and equal covariances; therefore, degrees of freedom were corrected using HuynhFeldt estimates of sphericity (ϵ = .999).
With respect to tests of within-subjects effects, the effect of time on depressive
symptomatology was not significant (F(1.998, 4648.855) = 1.613, n.s.), indicating that
endorsement of depressive symptomatology was consistent across the period of the study.
Within-subjects effects tests indicated a significant interaction between time and the sex of the
participant (F(1.998, 4648.855) = 5.493, p = .004), suggesting a significant difference in
depressive symptomatology between males and females across the period of the study. There
was no significant interaction between time and CVB in 1993 on depressive symptomatology
(F(1.998, 4648.855) = 0.259, n.s.), nor was there a significant interaction between time and
ApoE-conferred risk on depressive symptomatology (F(1.998, 4648.855) = 1.569, n.s.),
indicating no change in the effect that CVB or ApoE-conferred risk have on depressive
symptomatology as participants age. With respect to tests of between-subjects effects that do not
consider the effect of time, results indicated a significant main effect of education in 1993 (F(1,
2327) = 5.253, p = .022), CVB in 1993 (F(1, 2327) = 16.274, p < .001), sex (F(1, 2327) = 4.787,
p = .029), income in 1993 (F(4, 2327) = 4.476, p = .001), and marital status in 1993 (F(1, 2327)
= 14.077, p < .001) on depressive symptomatology. There was no significant between-subjects
effect of ApoE-conferred risk on depressive symptomatology (F(1, 2327) = 0.660, n.s.),
suggesting that ApoE-conferred risk has no effect on depressive symptomatology. LSD post-hoc
comparisons indicated that females endorsed significantly greater depressive symptomatology
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compared to males (F(1, 2327) = 4.787, p = .029), that married participants endorsed
significantly less depressive symptomatology compared to non-married participants (F(1, 2327)
= 14.077, p < .001), and that participants with higher income endorsed significantly less
depressive symptomatology compared to participants with lower income (F(4, 2327) = 4.476, p
= .008).
The longitudinal effect that ApoE-conferred risk has on the relationship between CVB
and depressive symptomatology over time was modeled by a moderated path analysis (Figure
2.2). Overall, results suggest that the hypothesized model fit the data very well (RMSEA=0.041;
Comparative Fit Index (CFI)=0.959, χ2(44, N=3203)=276.637, p<.00005). With respect to the
model’s autoregressive pathways evaluating the relationship demonstrating how previous CVB
affects future CVB, greater CVB in 1993 significantly predicted CVB in 2004 (β=0.498,
SE=0.013, p<.001). Further, greater CVB in 2004 was significantly associated with greater CVB
in 2011 (β=0.694, SE=0.009, p<.001). The autoregressive pathways demonstrating the
relationship between prior and future depressive symptomatology revealed a similar relationship,
whereby higher CES-D scores in 1993 were significantly associated with higher CES-D scores in
2004 (β=0.548, SE=0.013, p<.001), and higher CES-D scores in 2004 were significantly related
to higher CES-D scores in 2011 (β=0.594, SE=0.013, p<.001). With respect to the cross-lagged
pathways identifying the relationship between CVB and depressive symptomatology from
previous waves to future waves, greater CVB in 1993 was significantly associated with higher
CES-D scores in 2004 (β=0.037, SE=0.016, p=.018). Greater CVB in 2004 was a marginally
significant predictor of higher CES-D scores in 2011 (β=0.030, SE=0.016, p=.067). There was no
significant main effect of ApoE-conferred risk on depressive symptomatology in 2004 or 2011.
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The interaction between ApoE-conferred risk and CVB was not significant with respect
to depressive symptomatology in 2004 or 2011, indicating that ApoE does not moderate the
relationship between CVB and future depressive symptomatology. Overall, the model accounted
for 37.1% of the variance in depressive symptomatology in 2011.
In addition to the primary variables of interest, all control variables used in the model has
statistically significant pathways dependent upon the wave. Specifically, level of education was
significantly inversely related to the level of CVB in 1993 (β=-0.074, SE=0.019, p<.001), 2004
(β=-0.074, SE=0.016, p<.001), and 2011 (β=-0.033, SE=0.013, p=.012). Level of education was
also significantly inversely related to depressive symptomatology in 2004 (β=-0.036, SE=0.016,
p=.027) and 2011 (β=-0.039, SE=0.016, p=.017). Participant income was significantly inversely
associated with level of depressive symptomatology in 1993 (β=-0.127, SE=0.019, p<.001),
2004 (β=-0.040, SE=0.017, p=.017), and 2011 (β=-0.043, SE=0.017, p=.012). Sex of the
participant was significantly inversely associated with level of CVB in 1993 (β=-0.074,
SE=0.018, p<.001), 2004 (β=-0.100, SE=0.016, p<.001) and 2011(β=-0.064, SE=0.013, p<.001),
suggesting that male sex is associated with higher levels of CVB. Lastly, sex of the participant
was significantly associated with depressive symptomatology in 1993 (β=0.095, SE=0.018,
p<.001), and was marginally significantly associated with depressive symptomatology in 2004
(β=0.030, SE=0.016, p=.061), suggesting female sex was associated with higher depressive
symptomatology.
Discussion
ApoE has inconsistently been identified as a genetic risk factor for vascular depression.
The implication of ApoE carriage in various neurological diseases (e.g., AD, Wilson’s disease,
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and Parkinson’s disease; Blacker et al., 1997; Farrer et al., 1997; Li et al., 2004; Liu et al., 2013;
Schiefermeier et al., 2000) suggests a similar effect would exist for depression, given the
neurobiological components of disordered mood. The present study is the first of our knowledge
to evaluate the potential moderating effect of ApoE on the relationship between CVB and the
development of depressive symptomatology, while concurrently addressing the methodological
barriers identified in past work (e.g., small sample sizes, a sample younger than 65, and methods
that underrepresent at-risk individuals with respect to characteristics related to mortality-based
attrition, such as high depressive symptomatology, high CVB, and high levels of medical
burden).
The findings of the present study suggest that ApoE-conferred risk is not implicated in
the predisposition or perpetuation of depressive symptomatology, nor do they suggest ApoE as a
moderator of the effect of CVB on depressive symptomatology. These results exemplify the
intersection of two lines of research: (1) genetic risk factors for depression, and (2) genetic risk
factors for CVB, both of which have examined the influence of ApoE carriage. Our null findings
are consistent with extant research showing no significant association between ApoE and
depression, CVB, or their combination (Cervilla et al., 2004; Surtees et al., 2009). As
importantly, these results contradict previous findings that ApoE-4 carriage is linked to increased
risk for late-onset depression (Rigaud et al., 2001) as well as more severe depressive
symptomatology and incident minor depression in elders who were non-depressed at baseline 5years prior (Skoog et al., 2015).
The current study was pursued in the justifiable belief that ApoE would relate to
depressive symptomatology in the absence of methodological barriers common within the
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literature. The aforementioned methods included a longitudinal design, a large, appropriately
aged sample, and a solution to missing data to ensure that effects are not underrepresented due to
listwise deletion of individuals with missing data on variables associated with mortality-based
attrition. Our null results offer one potential explanation not of a methodological nature, but of
reporting bias: there may be a distorted portrayal of the influence of ApoE on depressive
symptomatology in the literature due to the difficulty associated with publishing null findings. It
is impossible to determine whether past findings of a relationship between ApoE carriage and
depressive symptomatology reflect type I error. Given that meta-analyses typically employ
published research, the underrepresentation of null findings in publicized literature may lead to
an undue overrepresented effect in these studies. Yet even with a potential misrepresentation of
the influence of ApoE on depressive symptomatology in the literature, one meta-analysis still
failed to find a significant effect of ApoE-4 on depression (Lopez-Leon et al., 2008).
The primary limitation of this study is the use of a racially homogeneous, well-educated
sample. The effect of ApoE on various neurological diseases such as AD has been shown to
fluctuate between ethnic groups (Tang et al., 1998). Future research should seek to replicate
these findings in a sample of greater racial and socioeconomic diversity. A second limitation of
this analysis is the use of self-reported health data in measuring CVB. However, this approach is
consistent with past research on clinically defined vascular depression, and subjective accounts
of medical burden have yielded high concordance with objective measures (e.g., medical records
and examinations; Bush et al., 1989; Psaty et al., 1995). A third limitation exists in the evaluation
of chronological change that is imposed by using only three defined time points over an extended
span of time (i.e., 18 years). To our knowledge, however, very few datasets exist that represent
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such a large number of participants from midlife to later-life, limiting the feasibility of a more
ideal analysis of these inter-relationships.
Future research should continue to examine the impact of ApoE on neurological
disorders, in conjunction with identifying alternative genetic risk factors for disordered health.
The imminent increase in the number of older adults over the next three decades makes the
identification of idiographic risk factors for disorders more prevalent in later-life critical. A
better understanding of the diatheses by which pathology develops will inherently lead to more
effective individualized treatments and subsequent improved collaboration across healthcare
providers.
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Table 1.1. Description of Characteristics of Sample, n = 5175.

Variable
Age
Education (years)
CES-D
CVB (range 0 to 3)
Household Income

1993
M (SD)
53.20 (0.62)
13.86 (2.37)
11.70 (6.98)
0.26 (0.50)
$56,000 ($50,800)

2004
M (SD)
64.31 (0.68)
13.88 (2.39)
10.19 (6.14)
0.71 (0.78)
$48,944 ($56,000)

2011
M (SD)
71.21 (0.93)
13.88 (2.39)
10.99 (6.69)
1.05 (0.89)
$33,260 ($35,930)
Percentage of
Sample
54.2
73.3
98.5
0.1
1.4

Female
Married
White
Black
Other race or refused to answer
*Household income represented by median and IQR.
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Table 1.2. Description of Characteristics of Sample, n = 3203.

Variable
Age
Education (years)
CES-D
CVB (range 0 to 3)
Household Income*

1993
M (SD)
53.17 (0.61)
13.97 (2.42)
11.61 (7.03)
0.25 (0.49)
$59,230 ($49,555)

2004
M (SD)
64.28 (0.66)
13.99 (2.44)
10.05 (5.96)
0.69 (0.77)
$53,144 ($55,440)

2011
M (SD)
71.08 (0.86)
13.99 (2.44)
10.78 (6.52)
1.03 (0.88)
$35,108 ($35,653)
Percentage of
Sample
53.5
75.7
98.6
0.1
1.3

Female
Married
White
Black
Other race or refused to answer
ApoE Carriage
e2/e2
e2/e3
e2/e4
e3/e3
e3/e4
e4/e4
*Household income represented by median and IQR.
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0.4
12.6
2.0
60.0
23.0
2.0
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Figure 2.1. The relationship between CVB and depressive symptomatology from mid-life to
later-life.
CVB = cerebrovascular burden.
D = depressive symptomatology.
§ denotes a significant relationship between the control variable and depressive symptomatology.
ɸ denotes a significant relationship between the control variable and CVB.
denotes p<.05.
denotes a n.s. relationship.
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Figure 2.2. The relationship between CVB and depressive symptomatology, and the moderating
effect of ApoE on that relationship, from mid-life to later-life.
CVB = cerebrovascular burden.
D = depressive symptomatology.
ApoE = apolipoprotein E-conferred risk.
§ denotes a significant relationship between the control variable and depressive symptomatology.
ɸ denotes a significant relationship between the control variable and CVB.
denotes p<.05.
denotes a n.s. relationship.
denotes marginal significance.
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